NTLA Intellia Therapeutics Inc.

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology

Intellia Therapeutics Congratulates Co-Founder Jennifer Doudna On Winning the 2020 Nobel Prize in Chemistry for Inventing the Revolutionary CRISPR/Cas9 Genome Editing Technology
EN
07/10/2020

Underlying

To request access to management, click here to engage with our
partner Phoenix-IR's CorporateAccessNetwork.com

Reports on Intellia Therapeutics Inc.

David Nierengarten ... (+3)
  • David Nierengarten
  • Dennis Pak
  • Martin Fan
 PRESS RELEASE

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Ne...

Intellia Therapeutics Presents Positive Longer-Term Phase 1 Data of Nexiguran Ziclumeran (nex-z) in Patients with Transthyretin (ATTR) Amyloidosis with Cardiomyopathy One-time treatment of nex-z led to consistently rapid, deep and durable reduction in serum TTR through three years of follow-upConsistent trend in disease stability or improvement in multiple measures of cardiomyopathy, regardless of NYHA Class, at 24 months compared to baselineLonger-term safety data consistent with previously reported Phase 1 data CAMBRIDGE, Mass., Nov. 10, 2025 (GLOBE NEWSWIRE) -- Intellia Therapeutics, ...

ResearchPool Subscriptions

Get the most out of your insights

Get in touch